Clinical Oncology Next Generation Sequencing (NGS) Market 2028 By Technology, Workflow, Application, End User and Geography | The Insight Partners

report image

Clinical Oncology Next Generation Sequencing (NGS) Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Technology (Whole Exome Sequencing, Whole Genome Sequencing, Targeted Sequencing and Resequencing); Workflow (NGS Data Analysis, NGS Pre-Sequencing, NGS Sequencing); Application (Companion Diagnostics, Screening, Other Applications); End User (Hospitals and Clinics, Laboratories) and Geography

Report Code: TIPRE00007163 | No. of Pages: 150 | Category: Biotechnology | Status: Upcoming


Next-generation sequencing is a technique for sequencing DNA or RNA that enables many reactions to be carried out simultaneously. NGS has transformed cancer genetics in recent years by providing researchers with access to genomic and transcriptomic data. In most of the developed nations the next generation sequencing method is used to develop cancer treatments through novel therapies.


The "Global Clinical Oncology Next Generation Sequencing (NGS) Market Analysis to 2028" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of the clinical oncology next generation sequencing (NGS) market with detailed market segmentation by technology, workflow, application and end user. The report provides key statistics on the market status of the leading clinical oncology next generation sequencing (NGS) market players and offers key trends and opportunities in the market.


  •   Based on technology the market is segmented as, whole exome sequencing, whole genome sequencing and targeted sequencing & resequencing.
  •   Based on workflow the market is segmented as, NGS data analysis, NGS pre-sequencing and NGS sequencing.
  •   Based on application the market is segmented as, companion diagnostics, screening and other applications.
  •   Based on end user the market is segmented as, hospitals & clinics and laboratories.


  •   Increasing prevalence of cancer along with technological advancement in the field of next generation sequencing.
  •   Increasing significance of next generation sequencing in cancer research.
  •   Decling cost of genome sequencing is also expected to fuel the market growth.


  •   However, dearth of skilled professionals, high cost associated with the study along with legal limitations associated with NGS are likely to restrain market growth.

Get more information on this report :


The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides an overview and forecast of the global market based on various segments. It also provides market size and forecast estimates from the year 2019 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), the Middle East and Africa (MEA), and South America. The clinical oncology next generation sequencing (NGS) market by each region is later sub-segmented by respective countries and segments. The report covers the analysis and forecast of 18 countries globally along with the current trend and opportunities prevailing in the region.

The report analyzes factors affecting the market from both demand and supply side and further evaluates market dynamics affecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA, and South America after evaluating political, economic, social and technological factors affecting the clinical oncology next generation sequencing (NGS) market in these regions.


COVID-19 first began in Wuhan (China) during December 2019 and since then it has spread at a fast pace across the globe. The US, India, Brazil, Russia, France, the UK, Turkey, Italy, and Spain are some of the worst affected countries in terms confirmed cases and reported deaths. The COVID-19 has been affecting economies and industries in various countries due to lockdowns, travel bans, and business shutdowns. Shutdown of various plants and factories has affected the global supply chains and negatively impacted the manufacturing, delivery schedules, and sales of products in global market. Few companies have already announced possible delays in product deliveries and slump in future sales of their products. According to the current market situation, the report further assesses the present and future effects of the COVID-19 pandemic on the overall market, giving more reliable and authentic projections In addition to this, the global travel bans imposed by countries in Europe, Asia-Pacific, and North America are affecting the business collaborations and partnerships opportunities.

Get more information on this report :


The report covers key developments in the clinical oncology next generation sequencing (NGS) market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the marketwere acquisitions, and partnership & collaborations. These activities have paved way for the expansion of business and customer base of market players. The market payers from clinical oncology next generation sequencing (NGS) market are anticipated to lucrative growth opportunities in the future with the rising demand for clinical oncology next generation sequencing (NGS) in the global market.

The report also includes the profiles of key companies along with their SWOT analysis and market strategies in the clinical oncology next generation sequencing (NGS) market. In addition, the report focuses on leading industry players with information such as company profiles, components, and services offered, financial information of the last 3 years, the key development in the past five years.

  •   Agilent Technologies, Inc.
  •   Caris Life Sciences
  •   F. Hoffmann-La Roche Ltd
  •   Illumina, Inc.
  •   Myriad Genetics, Inc.
  •   Oxford Nanopore Technologies
  •   PerkinElmer Inc
  •   QIAGEN
  •   Thermo Fisher Scientific Inc.
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.

Get more information on this report :

The List of Companies

1. Agilent Technologies, Inc.
2. Caris Life Sciences
3. F. Hoffmann-La Roche Ltd
5. Illumina, Inc.
6. Myriad Genetics, Inc.
7. Oxford Nanopore Technologies
8. PerkinElmer Inc
10. Thermo Fisher Scientific Inc.
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Get the Latest COVID-19 Analysis on this market

Have a Question?

Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

Speak to Analyst
  • $3000
  • $4550
  • $6550
  • $8550

Sample PDF showcases the content structure and the nature of the information included in the report which presents a qualitative and quantitative analysis.

    Inquire for Discount